Treatment of chronic gastritis is not an easy task for both the doctor and the patient. First of all, it requires considerable time, perseverance and endurance from both, and besides, sometimes a certain sanatorium-type environment [1,3,19].

The effectiveness of therapy depends not only on the knowledge of the doctor, his treatment tactics, not excluding the interaction of drugs, their pharmacokinetics and pharmacodynamics, but also on the adherence of patients, the characteristics of their genetic apparatus, which is not a little important in achieving the effect of the applied pharmacotherapy [2, 5, 9].

It is known that in the complex therapy of chronic gastritis, the diet occupies one of the most important places [15], therefore, in chronic gastritis with secretory insufficiency, diet No. 2 is selected, which consists of dishes sparing the mucous membranes of the stomach and stimulating gastric secretion [4, 6, 11]. Depending on the main clinical manifestations, therapeutic nutrition is selected individually.

Pharmacotherapy chronic gastritis is selected depending on the form of the disease, where the main role is played by the etiology, pathogenesis, clinical morphological picture of the disease. The tactics of treatment of chronic gastritis associated with H.pylori and non-associated are significantly different, but in both cases pharmacotherapy is selected based on the severity and activity of the pathological process with gastric mucosa, intestinal condition, as well as the activity of compensatory capabilities of the liver, pancreas and hepatobiliary system [5, 7].

Clinicians for the treatment of chronic gastritis prefer drugs from the group of PPIs, such as omeprozole, pantoprazole, lansoprazole, esomeprozole, as well as a drug from the group of antagonists of H-2-histaminoreceptors – famotidine (kvamatel), ranitidine, etc., selective M-cholinoblocking agents of the type – pirenzepine (gastrocepin), etc., drugs from the group antacids – almagel, its analogue almalel A, gastrogel, gelusil, phosphalyugel and the drug maalox, as well as prokinetics – for example, domperidone, etc. drugs [8, 10, 13].

The principles of pharmacotherapy for chronic gastritis may be standard, but the treatment of the disease cannot be the same for all patients, it must be personalized. This approach is based on the genetic characteristics of the patient.

Based on the above, it should be noted that the effectiveness of HG pharmacotherapy is directly influenced by the intensity of metabolism of first-line drugs - proton pump inhibitors, where the genetic feature of the patient plays an important role as a source of interindividual differences in the metabolic processes of pharmacological substances[12, 14, 18].

A number of studies are being conducted in the world aimed at studying the features and influence of polymorphisms of the CYP2C19 gene on the course and effectiveness of treatment of a number of diseases where this gene plays a particularly important role[6, 17]. In this regard, the main tasks of this direction are an in-depth analysis of the occurrence of genotypes of this gene, the peculiarities of the course of diseases depending on the genetic affiliation of the patient, their impact on the results and effectiveness of treatment and, depending on this, the improvement of pharmacotherapy[16, 20].

The purpose of the studyThe aim is to evaluate the effectiveness of treatment and determine the possibilities of personal pharmacotherapy by identifying the features of the occurrence of variants of the CYP2C19 gene genotype in patients with chronic gastritis.

In accordance with the objectives of the dissertation, a comprehensive examination was carried out in the scientific and genetic laboratory at the Olympic Committee of Uzbekistan, 80 unrelated patients with HG who were on inpatient treatment and observation at the Regional Multidisciplinary Clinical Hospital of the city of Bukhara and at Mohi Hossa. These patients made up the main comparison group.

The control group consisted of 20 healthy unrelated and without a history of gastrointestinal pathology persons who corresponded by gender and age to the examined group of patients with HG.

The age of patients with HG ranged from 15 to 79 years, men were 27 (33.8%), women – 53 (66.2%), that is, women significantly prevailed among patients with HG.

To achieve the goal and fulfill the tasks set, the following methods were used: general clinical examination of patients, laboratory-instrumental, molecular-genetic research methods, as well as methods of statistical processing of the data obtained.

it is known that the pharmacotherapy of HG varies depending on the form of the course and type of the disease, which serves to restore the structure and function of the stomach. However, the result of treatment may not always be what we would like. As a result of the selected pharmacotherapy by types of HG, the following results were obtained (Fig. 1):

HG type A - recovery – 57%, improvement – 43%, without improvement, deterioration and complications were not observed;

HG type B - recovery – 41%, improvement – 33%, without improvement – 10%, deterioration – 10%, complications - 5%;.

HG type C - recovery – 33%, improvement – 33%, without improvement – 20%, deterioration – 7%, complications - 7%.

Thus, the pharmacotherapy of HG has different effects depending on the type of HG. Thus, HG type is treatable and there were no worsening and complications of the disease; whereas after pharmacotherapy, HG type C is effective only in 1/3 of patients and it should be noted that there are cases of complications and worsening of the disease. Adequate efficacy of pharmacotherapy was not observed in the type of HG. After this therapy, 1/10 of the patients' condition worsened and 1/20 of the patients had complications of the disease.

Therefore, a personalized approach to each patient in the selection of drugs for treatment is the most optimal pharmacotherapy tactic. Such an individual approach should be based on the genetic characteristics of the patient according to the drugs selected for treatment. Methods of genotyping patients provides an increase in the effectiveness and safety of pharmacotherapy, which is the main task of clinical pharmacology, therapy and medicine in general.